Sameek Roychowdhury, MD, PhD, on Telemedicine in Clinical Trials
2025 ASCO Annual Meeting
Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedicine clinical trial of pemigatinib in patients with advanced or metastatic FGFR-mutated pancreatic cancer, and the germination of a new initiative, TNT Cancer, which focuses on leveraging telemedicine to bring trials nationwide.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I'd love to tell you about our new nationwide telemedicine clinical trial for pancreas cancer with FGFR gene fusions or mutations. This is a first-of-its-kind telemedicine-only study where we can reach patients from the entire United States of America. This was inspired by several patients that we've treated on FGFR basket trials with pancreas cancer. The patients did very well, living three to five years with their metastatic disease with FGFR kinase inhibitors. So this was the inspiration for this study, which was also driven by what we learned from COVID. Many of the investigators running clinical trials from 2020 to 2021 had to make some adjustments, and we all got used to telemedicine, doing things remotely, getting tests done remotely. With that, we realized that it was possible. We had treated a couple of patients with FGFR kinase inhibitors, and when we thought about pancreas cancer—this was a disease that would probably not have a drug developed for it when the FGFR gene fusion is about 1% of pancreas cancer—we think that's about 500 patients per year, which is a sizable population of people who can benefit. But when it comes to developing a drug with the traditional trial format, it’s very costly and maybe not worth the economic investment. So instead of a $30 million trial, we could do a trial for just over $2 million for 40 patients with FGFR fusion–positive pancreas cancer. The study includes patients with fusions for FGFR 1, 2, and 3, as well as activating mutations for the same receptors. It’s been open since May—it just opened. We're evaluating our first patient all the way from Alabama. The patient never has to travel. We work hand in hand with the local oncologist. They don't do any of the study-specific activities—only we do that. They will help us do CAT scans and blood work, but we will manage the drug, the dose, the assessment of side effects, and so forth as the trial lead. There are no other sub-sites, so it reduces the cost. There's no extra regulatory paperwork. So there's no sub-sites. We're hoping that people will learn about this study. We are accepting referrals, so please reach out to me if you have a candidate patient. We'll be happy to work with you to evaluate them. We also want other investigators to work with us to implement new clinical trials using telemedicine. We want to share what we are doing, and we want to learn from you. We're launching an effort called TNT Cancer—TNT: Telemedicine Nationwide Therapeutics for Cancer. We want to partner with other investigators who want to do this too. So we look forward to meeting all of you and evaluating your patients.
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.
The ASCO Post Staff
Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508).
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501).
The ASCO Post Staff
David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, reviews data on the role of a 14-gene molecular assay in selecting patients with stage IA–IIA non–small cell lung cancer (NSCLC) as high risk (LBA8027).